Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation

Drug Metabolism and Pharmacokinetics

Volumn 30, Issue 5, 2015, Pages 366-373

  Tsukada, Chiharu ^a   Saito, Takahiro ^a   Maekawa, Masamitsu ^b   Mano, Nariyasu ^b   Oda, Akifumi ^c   Hirasawa, Noriyasu ^a   Hiratsuka, Masahiro ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

Amodiaquine; CYP2C8; Cytochrome P450; Genetic polymorphisms; Paclitaxel

Indexed keywords

AMODIAQUINE; CYTOCHROME P450 2C8; DEETHYLAMODIAQUINE; DOCETAXEL; OXYGENASE; PACLITAXEL; CYP2C8 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; ENZYME ACTIVITY; GENETIC VARIABILITY; HUMAN; HYDROXYLATION; IN VITRO STUDY; KINETIC PARAMETERS; PROTEIN EXPRESSION; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICAL STRUCTURE; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; GENE VECTOR; GENETIC POLYMORPHISM; GENETIC VARIATION; GENETICS; METABOLISM; MOLECULAR CLONING;

ALLELES; AMODIAQUINE; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CERCOPITHECUS AETHIOPS; CLONING, MOLECULAR; COS CELLS; CYTOCHROME P-450 CYP2C8; GENETIC VARIATION; GENETIC VECTORS; HUMANS; HYDROXYLATION; MODELS, MOLECULAR; PACLITAXEL; POLYMORPHISM, GENETIC;

EID: 84943514846     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.1016/j.dmpk.2015.07.003     Document Type: Article

References (35)

1. X.S. Lai, L.P. Yang, X.T. Li, J.P. Liu, Z.W. Zhou, and S.F. Zhou Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms Curr Drug Metab 10 2009 1009 1047
2. C.L. Aquilante, M. Niemi, L. Gong, R.B. Altman, and T.E. Klein PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8 Pharmacogenet Genomics 23 2013 721 728
3. D. Dai, D.C. Zeldin, J.A. Blaisdell, B. Chanas, S.J. Coulter, B.I. Ghanayem, and et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid Pharmacogenetics 11 2001 597 607
4. L. Yu, D. Shi, L. Ma, Q. Zhou, and S. Zeng Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro Biopharm Drug Dispos 34 2013 278 287
5. R. Kaspera, S.B. Naraharisetti, E.A. Evangelista, K.D. Marciante, B.M. Psaty, and R.A. Totah Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5 Biochem Pharmacol 82 2011 681 691
6. R. Kaspera, S.B. Naraharisetti, B. Tamraz, T. Sahele, M.J. Cheesman, P.Y. Kwok, and et al. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis Pharmacogenet Genomics 20 2010 619 629
7. H. Steed, and M.B. Sawyer Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel Pharmacogenomics 8 2007 803 815
8. R. Taniguchi, T. Kumai, N. Matsumoto, M. Watanabe, K. Kamio, S. Suzuki, and et al. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4 J Pharmacol Sci 97 2005 83 90
9. D.S. Sonnichsen, Q. Liu, E.G. Schuetz, J.D. Schuetz, A. Pappo, and M.V. Relling Variability in human cytochrome P450 paclitaxel metabolism J Pharmacol Exp Ther 275 1995 566 575
10. D.L. Hertz, A.A. Motsinger-Reif, A. Drobish, S.J. Winham, H.L. McLeod, L.A. Carey, and et al. CYP2C8∗3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel Breast Cancer Res Treat 134 2012 401 410
11. H. Green, P. Soderkvist, P. Rosenberg, R.A. Mirghani, P. Rymark, E.A. Lundqvist, and et al. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer Basic Clin Pharmacol Toxicol 104 2009 130 137
12. T.K. Bergmann, C. Brasch-Andersen, H. Green, M. Mirza, R.S. Pedersen, F. Nielsen, and et al. Impact of CYP2C8∗3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer Pharmacogenomics J 11 2011 113 120
13. J.E. Abraham, Q. Guo, L. Dorling, J. Tyrer, S. Ingle, R. Hardy, and et al. Replication of genetic polymorphisms reported to be associated with Taxane-related sensory neuropathy in early breast cancer patients treated with paclitaxel Clin Cancer Res 20 2014 2466 2475
14. S. Leskela, C. Jara, L.J. Leandro-Garcia, A. Martinez, J. Garcia-Donas, S. Hernando, and et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity Pharmacogenomics J 11 2011 121 129
15. H. Green, M.S. Khan, I. Jakobsen-Falk, E. Avall-Lundqvist, and C. Peterson Impact of CYP3A5∗3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer J Pharm Sci 100 2011 4205 4209
16. D.L. Hertz, S. Roy, J. Jack, A.A. Motsinger-Reif, A. Drobish, L.S. Clark, and et al. Genetic heterogeneity beyond CYP2C8∗3 does not explain differential sensitivity to paclitaxel-induced neuropathy Breast Cancer Res Treat 145 2014 245 254
17. Y. Saito, N. Katori, A. Soyama, Y. Nakajima, T. Yoshitani, S.R. Kim, and et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population Pharmacogenet Genomics 17 2007 461 471
18. Y. Gao, D. Liu, H. Wang, J. Zhu, and C. Chen Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions Xenobiotica 40 2010 467 475
19. S. Parikh, J.B. Ouedraogo, J.A. Goldstein, P.J. Rosenthal, and D.L. Kroetz Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa Clin Pharmacol Ther 82 2007 197 203
20. A. Soyama, Y. Saito, N. Hanioka, N. Murayama, O. Nakajima, N. Katori, and et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism Biol Pharm Bull 24 2001 1427 1430
21. A. Soyama, Y. Saito, K. Komamura, K. Ueno, S. Kamakura, S. Ozawa, and et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift Drug Metab Pharmacokinet 17 2002 374 377
22. H. Jiang, F. Zhong, L. Sun, W. Feng, Z.X. Huang, and X. Tan Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8 Amino Acids 40 2011 1195 1204
23. R. Singh, J.G. Ting, Y. Pan, L.K. Teh, R. Ismail, and C.E. Ong Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity Drug Metab Pharmacokinet 23 2008 165 174
24. H. Hichiya, T. Tanaka-Kagawa, A. Soyama, H. Jinno, S. Koyano, N. Katori, and et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population Drug Metab Dispos 33 2005 630 636
25. N. Hanioka, K. Matsumoto, Y. Saito, and S. Narimatsu Influence of CYP2C8∗13 and CYP2C8∗14 alleles on amiodarone N-deethylation Basic Clin Pharmacol Toxicol 108 2011 359 362
26. N. Hanioka, K. Matsumoto, Y. Saito, and S. Narimatsu Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel Basic Clin Pharmacol Toxicol 107 2010 565 569
27. A. Soyama, N. Hanioka, Y. Saito, N. Murayama, M. Ando, S. Ozawa, and et al. Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8∗3 and CYP2C8 P404A Pharmacol Toxicol 91 2002 174 178
28. C. Ishikawa, H. Ozaki, T. Nakajima, T. Ishii, S. Kanai, S. Anjo, and et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin J Hum Genet 49 2004 582 585
29. P.V. Dravid, and R.F. Frye Determination of N-desethylamodiaquine by hydrophilic interaction liquid chromatography with tandem mass spectrometry: application to in vitro drug metabolism studies J Chromatogr B Anal Technol Biomed Life Sci 863 2008 129 134
30. G.A. Schoch, J.K. Yano, M.R. Wester, K.J. Griffin, C.D. Stout, and E.F. Johnson Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site J Biol Chem 279 2004 9497 9503
31. C.L. Aquilante, M.F. Wempe, S.H. Spencer, L.A. Kosmiski, J.A. Predhomme, and M.S. Sidhom Influence of CYP2C8∗2 on the pharmacokinetics of pioglitazone in Healthy African-American Volunteers Pharmacotherapy 33 2013 1000 1007
32. C.W. Yeo, S.J. Lee, S.S. Lee, S.K. Bae, E.Y. Kim, J.H. Shon, and et al. Discovery of a novel allelic variant of CYP2C8, CYP2C8∗11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo Drug Metab Dispos 39 2011 711 716
33. L. Afzelius, F. Raubacher, A. Karlen, F.S. Jorgensen, T.B. Andersson, C.M. Masimirembwa, and et al. Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques Drug Metab Dispos 32 2004 1218 1229
34. D.F. Lewis Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure Xenobiotica 32 2002 305 323
35. S. Ohtsuki, O. Schaefer, H. Kawakami, T. Inoue, S. Liehner, A. Saito, and et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities Drug Metab Dispos 40 2012 83 92